Anton Lauren, Sierra Luz-Jeannette, DeVine Ann, Barila Guillermo, Heiser Laura, Brown Amy G, Elovitz Michal A
Department of Obstetrics and Gynecology, Maternal and Child Health Research Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Front Microbiol. 2018 Oct 8;9:2181. doi: 10.3389/fmicb.2018.02181. eCollection 2018.
Cervicovaginal (CV) microbiota is associated with vaginal health and disease in non-pregnant women. Recent studies in pregnant women suggest that specific CV microbes are associated with preterm birth (PTB). While the associations between CV microbiota and adverse outcomes have been demonstrated, the mechanisms regulating the associations remain unclear. As the CV space contains an epithelial barrier, we postulate that CV microbiota can alter the epithelial barrier function. We investigated the biological, molecular, and epigenetic effects of , and on the cervical epithelial barrier function and determined whether mitigates the effects of lipopolysaccharide (LPS) and on the cervical epithelial barrier as a possible mechanism by which CV microbiota mitigates disease risk. Ectocervical and endocervical cells treated with , and bacteria-free supernatants alone or combined were used to measure cell permeability, adherens junction proteins, inflammatory mediators, and miRNAs. Ectocervical and endocervical permeability increased after and exposure. Soluble epithelial cadherin increased after exposure to but not or . A Luminex cytokine/chemokine panel revealed increased proinflammatory mediators in all three bacteria-free supernatants with and having more diverse inflammatory effects. and altered the expression of cervical-, microbial-, and inflammatory-associated miRNAs. mitigated the LPS or -induced disruption of the cervical epithelial barrier and reversed the -mediated increase in miRNA expression. colonization of the CV space of a pregnant C57/B6 mouse resulted in 100% PTB. These findings demonstrate that and alter the cervical epithelial barrier by regulating adherens junction proteins, cervical immune responses, and miRNA expressions. These results provide evidence that confers protection to the cervical epithelial barrier by mitigating LPS- or -induced miRNAs associated with cervical remodeling, inflammation, and PTB. This study provides further evidence that the CV microbiota plays a role in cervical function by altering the cervical epithelial barrier and initiating PTB. Thus, targeting the CV microbiota and/or its effects on the cervical epithelium may be a potential therapeutic strategy to prevent PTB.
宫颈阴道(CV)微生物群与非孕妇的阴道健康和疾病相关。最近对孕妇的研究表明,特定的CV微生物与早产(PTB)有关。虽然CV微生物群与不良结局之间的关联已得到证实,但调节这些关联的机制仍不清楚。由于CV区域存在上皮屏障,我们推测CV微生物群可改变上皮屏障功能。我们研究了[具体微生物1]和[具体微生物2]对宫颈上皮屏障功能的生物学、分子和表观遗传学影响,并确定[具体微生物1]是否减轻脂多糖(LPS)和[具体微生物2]对宫颈上皮屏障的影响,这可能是CV微生物群减轻疾病风险的一种机制。单独或联合使用[具体微生物1]和[具体微生物2]的无菌上清液处理宫颈外口和宫颈内口细胞,以测量细胞通透性、黏附连接蛋白、炎症介质和微小RNA(miRNA)。暴露于[具体微生物1]和[具体微生物2]后,宫颈外口和宫颈内口的通透性增加。暴露于[具体微生物1]后可溶性上皮钙黏蛋白增加,但暴露于[具体微生物2]或[具体微生物3]后未增加。Luminex细胞因子/趋化因子检测显示,所有三种无菌上清液中的促炎介质均增加,其中[具体微生物1]和[具体微生物2]具有更多样化的炎症作用。[具体微生物1]和[具体微生物2]改变了宫颈、微生物和炎症相关miRNA的表达。[具体微生物1]减轻了LPS或[具体微生物2]诱导的宫颈上皮屏障破坏,并逆转了[具体微生物2]介导的miRNA表达增加。怀孕的C57/B6小鼠的CV区域定殖[具体微生物2]导致100%早产。这些发现表明,[具体微生物1]和[具体微生物2]通过调节黏附连接蛋白、宫颈免疫反应和miRNA表达来改变宫颈上皮屏障。这些结果提供了证据,表明[具体微生物1]通过减轻与宫颈重塑、炎症和早产相关的LPS或[具体微生物2]诱导的miRNA,为宫颈上皮屏障提供保护。本研究提供了进一步的证据,表明CV微生物群通过改变宫颈上皮屏障和引发早产在宫颈功能中发挥作用。因此,针对CV微生物群及其对宫颈上皮的影响可能是预防早产的一种潜在治疗策略。